This year will be ugly for Eli Lilly and Co., after the recent loss of two blockbusters, but it also gives Lilly an opportunity it hasn’t really had for nearly a decade: grow sales and profit by launching new drugs.
Testosterone drugs, which make up a growing market for pharmaceutical companies such as Eli Lilly, are getting a closer look from U.S. regulators.
Paris-based Sanofi sued Eli Lilly and Co. on Thursday for patent infringement. That suit triggers an automatic 30-month delay on Lilly’s plans to launch a similar version of Sanofi’s once-a-day insulin Lantus.
The Indianapolis drugmaker said gains in other products offset declines for its top drug Cymbalta, which lost patent protection in December. Overall, sales slipped 2 percent, to $5.8 billion.
A newspaper says Eli Lilly and Co. is a leading contender to acquire a Massachusetts-based biotech company with a troubled leukemia drug.
Positive results from a Phase 2 trial in patients convinced Lilly to reacquire an experimental migraine medicine. Lilly recorded a charge of $57 million to reflect the purchase price and the costs of further development.
In a warning shot to investors, the pharmaceutical giant says it expects “2014 to be the most financially challenging year of Lilly’s current period of patent expirations.”
Obamacare has officially arrived, but both conservatives and liberals are calling it awful. That means the real debate over health reform is just beginning.
Eli Lilly and Co., Pfizer Inc., Sanofi and other large drugmakers will keep paying doctors to give talks about their products, leaving GlaxoSmithKline Plc alone for now in its decision to halt such compensation.
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
Cymbalta is Eli Lilly and Co. Inc.'s best-selling drug and posted 2012 sales of $4.7 billion, making it the fifth-highest selling medication in the world. The drug's patent expired Wednesday.
Eli Lilly and Co. on Wednesday will fall off its second “patent cliff” in as many years as its best-selling drug Cymbalta sees its U.S. patents expire.
Edivoxetine, a derivative of Lilly's Strattera drug for attention deficit disorder, was in the final of three stages of testing usually required for marketing approval by U.S. regulators.
Indianapolis-based Eli Lilly and Co. has joined two other companies to contribute $40 million to an early-stage life sciences venture capital initiative in New York City.
Novartis AG’s animal-health business is drawing interest from drugmakers including Indianapolis-based Eli Lilly and Co. and Merck & Co. as the Swiss pharmaceutical giant prepares to sell the unit, people with knowledge of the matter said.
It’s no secret the growth of the U.S. economy slowed in the 2000s after the go-go decade preceding it. But the U.S. health care system—hospitals, doctors, drug companies, device makers and health insurers—apparently didn’t get that memo.
The move includes a $45 million investment for Lilly's operations in Indianapolis, on top of $400 million in investments the company announced over the past two years.
Eli Lilly and Co. and Pfizer Inc., which are both suffering through some of the largest patent cliffs in the industry, will split any future costs and profits of an osteoarthritis drug that has stalled in clinical testing.
Testosterone replacement drugs, a $1.6 billion market for Eli Lilly and Co. and others, boosted the odds of having a heart attack, stroke or dying by 29 percent in one of the first studies weighing the therapy's cardiovascular risks.
Indianapolis-based Eli Lilly and Co., Bayer AG and Boehringer Ingelheim GmbH are among companies that may consider an offer if the Swiss drugmaker proceeds with the animal-health sale.
